Antares Pharma didn't impress the market with its Q1 results, but a pending Food and Drug Administration decision on Otrexup might be a game changer for this small biotech. Results Antares reported a ...
Shares of self injection drug delivery technology company Antares Pharma, Inc. (ATRS) are trading higher on Monday after the U.S. Food and Drug Administration approved Otrexup, a once-per-week ...
EWING, N.J. (AP) -- Shares of Antares Pharma Inc. climbed Wednesday after the drug developer said U.S. regulators will review its application for the potential rheumatoid arthritis and psoriasis ...
Antares Pharma announced the approval of OTREXUP injection by the Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an ...
Certain adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis (pJIA), after treatment with other medicines including non-steroidal ...
Please provide your email address to receive an email when new articles are posted on . Antares Pharma has announced that LEO Pharma has launched Antares’ subcutaneous methotrexate product Otrexup to ...
Antares Pharma announced its first-quarter results Wednesday morning but failed to impress the market. Shares were down around 3% in midday trading. Here are the highlights from the company's results.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results